Ifosfamide and etoposide as salvage therapy for non‐Hodgkin's lymphoma

Abstract

The result of a combination consisting of ifosfamide and etoposide was evaluated in 57 patients suffering from non-Hodgkin's lymphoma (NHL) who had relapsed or were resistant to adriamycin-containing combinations. Some of the patients (35%) also received methotrexate. 80% of the patients belonged to the histology group 'high-grade' malignant NHL. 11 of the 57 patients (19%) obtained a remission, 5 of these were complete and 6 partial. The remission predominantly occurred in the group of patients with 'high-grade' malignant histopathology who were treated at the first relapse after complete remission or when front-line treatment induced a partial remission and ifosfamide and etoposide were added in direct connection with front-line treatment. It is concluded that the use of the combination of ifosfamide and etoposide should be limited to such patients.

Related Papers

• → Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A pediatric oncology group study(1993)6 cited
• → A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma(1997)5 cited
• → Ifosfamide and Etoposide Salvage Treatment in Advanced Ovarian Cancer(1991)5 cited
• → Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors(1982)28 cited
• → Outcome and Toxicity of an Ifosfamide‐Based Soft Tissue Sarcoma Treatment Protocol in Children. The Importance of Local Therapy(1998)